Create Medicines raised $122 million in a Series B round to advance its in vivo CAR-T platform across autoimmune disease and oncology programs, with early clinical dosing already underway. The company’s mRNA-LNP system programs T cells, NK cells, and myeloid cells inside the body, aiming for repeat-dose “one-day manufacturing” compared with conventional ex vivo cell therapy workflows. Create says it has dosed more than 50 patients across its programs. The Series B round is intended to support progression of the lead autoimmune program, CRT-402 (CD19-targeted in vivo CAR T), and additional candidates, including oncology programs such as MT-303 in frontline hepatocellular carcinoma. The company also highlighted a clinical start for MT-304 targeting HER2-positive solid tumors and other HER2 expressions. For the sector, the financing reinforces investor appetite for in vivo cell therapy approaches that reduce manufacturing bottlenecks—particularly relevant as CAR-T access and scale remain ongoing industry constraints.